Surmodics | SRDX - Assets


Surmodics reported $169.82M in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
Align Technology USD 6.31B 80.48M Mar/2026
Anika Therapeutics USD 179.39M 10.88M Mar/2026
Arrowhead Research USD 1.6B 218.89M Dec/2025
Artivion USD 884.8M 27.13M Dec/2025
Baxter International USD 19.85B 209M Mar/2026
Boston Scientific USD 44.35B 678M Mar/2026
EDAP TMS EUR 61.46M 6.88M Sep/2025
Edwards Lifesciences USD 13.7B 425M Dec/2025
Haemonetics USD 2.49B 48.73M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
J&J USD 200.89B 1.68B Mar/2026
Merit Medical Systems USD 2.72B 33.36M Mar/2026
Mesa Laboratories USD 434.85M 4.5M Dec/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Option Care Health USD 3.38B 75.67M Mar/2026
Stryker USD 46.29B 1.55B Mar/2026
Surmodics USD 169.82M 8.74M Jun/2025
Trinity Biotech USD 103.71M 4.08M Sep/2025